Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

DOI record: { "DOI": "10.1101/2020.09.23.20199463", "URL": "http://dx.doi.org/10.1101/2020.09.23.20199463", "abstract": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Famotidine has been posited as a potential treatment for COVID-19. We compared the incidence of COVID-19 outcomes (i.e., death; and death or intensive services use) among hospitalized famotidine users vs. proton pump inhibitors (PPIs) users, hydroxychloroquine users or famotidine non-users separately.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We constructed a retrospective cohort study using data from COVID-19 Premier Hospital electronic health records. Study population were COVID-19 hospitalized patients aged 18 years or older. Famotidine, PPI and hydroxychloroquine exposure groups were defined as patients dispensed any medication containing one of the three drugs on the day of admission. The famotidine non-user group was derived from the same source population with no history of exposure to any drug with famotidine as an active ingredient prior to or on the day of admission. Time-at-risk was defined based on the intention-to-treat principle starting 1 day after admission to 30 days after admission. For each study comparison group, we fit a propensity score (PS) model through large-scale regularized B logistic regression. The outcome was modeled using a survival model.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We identified 2193 users of PPI, 5950 users of the hydroxychloroquine, 1816 users of famotidine and 26,820 non-famotidine users. After PS stratification, the hazard ratios for death were as follows: famotidine vs no famotidine HR 1.03 (0.89-1.18); vs PPIs: HR 1.14 (0.94-1.39); vs hydroxychloroquine:1.03 (0.85-1.24). Similar results were observed for the risk of death or intensive services use.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We found no evidence of a reduced risk of COVID-19 outcomes among hospitalized COVID-19 patients who used famotidine compared to those who did not or compared to PPI or hydroxychloroquine users.</jats:p></jats:sec>", "accepted": { "date-parts": [ [ 2020, 9, 24 ] ] }, "author": [ { "ORCID": "http://orcid.org/0000-0002-6976-2594", "affiliation": [], "authenticated-orcid": false, "family": "Shoaibi", "given": "Azza", "sequence": "first" }, { "affiliation": [], "family": "Fortin", "given": "Stephen", "sequence": "additional" }, { "affiliation": [], "family": "Weinstein", "given": "Rachel", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9810-745X", "affiliation": [], "authenticated-orcid": false, "family": "Berlin", "given": "Jesse A.", "sequence": "additional" }, { "affiliation": [], "family": "Ryan", "given": "Patrick", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 9, 24 ] ], "date-time": "2020-09-24T15:00:17Z", "timestamp": 1600959617000 }, "deposited": { "date-parts": [ [ 2021, 2, 15 ] ], "date-time": "2021-02-15T03:30:53Z", "timestamp": 1613359853000 }, "group-title": "Gastroenterology", "indexed": { "date-parts": [ [ 2023, 3, 16 ] ], "date-time": "2023-03-16T12:51:00Z", "timestamp": 1678971060070 }, "institution": [ { "name": "medRxiv" } ], "is-referenced-by-count": 4, "issued": { "date-parts": [ [ 2020, 9, 24 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2020.09.23.20199463", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2020, 9, 24 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2020, 9, 24 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference": [ { "DOI": "10.21203/rs.3.rs-30934/v1", "doi-asserted-by": "crossref", "key": "2021021109351118000_2020.09.23.20199463v1.1", "unstructured": "Malone RW , Tisdall P , Fremont-Smith P , et al. COVID-19: Famotidine, histamine, mast cells, and mechanisms. 2020." }, { "DOI": "10.1016/S0149-2918(96)80177-9", "article-title": "The tolerability and safety profile of famotidine", "doi-asserted-by": "crossref", "first-page": "36", "journal-title": "Clinical therapeutics", "key": "2021021109351118000_2020.09.23.20199463v1.2", "volume": "18", "year": "1996" }, { "DOI": "10.23812/Editorial-Conti-3", "doi-asserted-by": "publisher", "key": "2021021109351118000_2020.09.23.20199463v1.3" }, { "DOI": "10.1016/j.apsb.2020.02.008", "doi-asserted-by": "crossref", "key": "2021021109351118000_2020.09.23.20199463v1.4", "unstructured": "Wu C , Liu Y , Yang Y , et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 2020." }, { "article-title": "The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents", "first-page": "PL365", "journal-title": "Life sciences", "key": "2021021109351118000_2020.09.23.20199463v1.5", "volume": "59", "year": "1996" }, { "DOI": "10.1053/j.gastro.2020.05.053", "doi-asserted-by": "crossref", "key": "2021021109351118000_2020.09.23.20199463v1.6", "unstructured": "Freedberg DE , Conigliaro J , Wang TC , et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology 2020." }, { "DOI": "10.14309/ajg.0000000000000832", "doi-asserted-by": "crossref", "key": "2021021109351118000_2020.09.23.20199463v1.7", "unstructured": "Mather JF , Seip RL , McKay RG . Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19. Official journal of the American College of Gastroenterology| ACG 2020." }, { "DOI": "10.1158/1557-3265.COVID-19-S04-01", "doi-asserted-by": "crossref", "key": "2021021109351118000_2020.09.23.20199463v1.8", "unstructured": "Janowitz T , Gablenz E , Pattinson D , et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut 2020." }, { "DOI": "10.1053/j.gastro.2020.05.098", "doi-asserted-by": "crossref", "key": "2021021109351118000_2020.09.23.20199463v1.9", "unstructured": "Cheung KS , Hung IF , Leung WK . Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study. Gastroenterology 2020." }, { "key": "2021021109351118000_2020.09.23.20199463v1.10", "unstructured": "Premier Healthcare Database: Data That Informs and Performs. Premier website. https://products.premierinc.com/downloads/PremierHealthcareDatabaseWhitepaper.pdf.." }, { "article-title": "A tool for assessing the feasibility of comparative effectiveness research", "first-page": "11", "journal-title": "Comp Eff Res", "key": "2021021109351118000_2020.09.23.20199463v1.11", "volume": "2013", "year": "2013" }, { "DOI": "10.1080/03610910902859574", "doi-asserted-by": "publisher", "key": "2021021109351118000_2020.09.23.20199463v1.12" }, { "DOI": "10.1016/S0140-6736(19)32317-7", "article-title": "Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis", "doi-asserted-by": "crossref", "first-page": "1816", "journal-title": "The Lancet", "key": "2021021109351118000_2020.09.23.20199463v1.13", "volume": "394", "year": "2019" } ], "reference-count": 13, "references-count": 13, "relation": {}, "resource": { "primary": { "URL": "http://medrxiv.org/lookup/doi/10.1101/2020.09.23.20199463" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "subtype": "preprint", "title": "Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients", "type": "posted-content" }